Our Ref: 060/2020
February 2020

Doncaster and Bassetlaw Teaching Hospitals
NHS Foundation Trust

## Re: Your request made under the Freedom of Information Act 2000

1) Is the branded biosimilar AMGEVITA listed on your formulary for (a) rheumatology **Yes**, (b) dermatology **Yes**, and (c) gastroenterology **Yes**

2) Please complete the number of patients prescribed with the following products in the last 12 months:

   AMGEVITA first-line*
   AMGEVITA second-line*
   HUMIRA first-line*
   HUMIRA second-line*
   HYRIMOZ first-line*
   IMRALDI first-line*

   Within (a) Rheumatology, (b) Dermatology and (c) Gastroenterology:

   **We do not have sufficient access to this information.**

**How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway. For example, according to the NICE Pathway, psoriasis patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.*

3) Are any local guidelines followed that recommend earlier use of anti-TNF biologics/ biosimilars in the treatment pathway for:

   **We do not have sufficient access to this information.**

   Dermatology:
   a) Psoriasis
   Rheumatology:
   b) Psoriatic arthritis
   c) Rheumatoid arthritis
   d) Ankylosing spondylitis
   Gastroenterology:
   e) Crohn's disease
   f) Ulcerative colitis

Are there occasions where patients can receive adalimumab outside of NICE/SMC/AWMSG/National criteria for?

   Dermatology:
   a) Psoriasis
   Rheumatology:
   b) Psoriatic arthritis
   c) Rheumatoid arthritis
   d) Ankylosing spondylitis
   Gastroenterology:
   e) Crohn's disease
   f) Ulcerative colitis

4) What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs/Health Boards?
   Block contracts? **No**
   Fixed price on a patient-by-patient basis? **Yes**